118 related articles for article (PubMed ID: 8066631)
1. Effect of DST combined with cyclosporine on lymphocyte subsets of potential recipients for living-related donor renal allograft.
Murai M; Nakamura H; Sekiguchi S; Shimizu S; Nakajima F
Transplant Proc; 1994 Aug; 26(4):1950-1. PubMed ID: 8066631
[No Abstract] [Full Text] [Related]
2. Spleen mixed leukocyte chimerism and induction of tolerance in rat renal allograft recipients conditioned with donor-specific blood transfusions and cyclosporine.
Llull R; Mañez R; Domenech N; Starzl TE; Black KS; Hewitt CW
Transplant Proc; 1995 Aug; 27(4):2374-6. PubMed ID: 7652844
[No Abstract] [Full Text] [Related]
3. Donor-specific blood transfusions (DST): clinical outcome and immunologic considerations.
Fujiwara T; Sakagami K; Haisa M; Kusaka S; Uda M; Kobayashi N; Tanakaya K; Saito S; Matsuno T; Matsuoka J
Transplant Proc; 1992 Aug; 24(4):1427-8. PubMed ID: 1386699
[No Abstract] [Full Text] [Related]
4. [The dependence of the efficacy of cyclosporin A use in a kidney allograft on the degree of donor and recipient tissue compatibility based on HLA-DR antigens].
Abramov VIu; Kaluzhina NN; Otocheva LV; Zaretskaia IuM
Urol Nefrol (Mosk); 1993; (4):27-30. PubMed ID: 8310562
[TBL] [Abstract][Full Text] [Related]
5. Donor-specific transfusion (DST) with intermittent administration of azathioprine induces suppressor T cells and MLR-inhibiting factors without sensitization.
Haisa M; Sakagami K; Matsumoto T; Kawamura T; Uchida S; Fujiwara T; Shiozaki S; Inagaki M; Orita K
Transplant Proc; 1989 Feb; 21(1 Pt 2):1814-7. PubMed ID: 2523594
[No Abstract] [Full Text] [Related]
6. Effect of ultraviolet-B-irradiated donor-specific blood transfusion and cyclosporine on cardiac allograft survival and mixed lymphocyte reaction in rats.
Koh YB; Park IY; Lee YK
Transplant Proc; 1994 Aug; 26(4):1952-3. PubMed ID: 8066632
[No Abstract] [Full Text] [Related]
7. Clinical immunosuppression, lymphocyte subsets, and host defense mechanisms.
Guttmann RD
Transplant Proc; 1994 Aug; 26(4):1847. PubMed ID: 8066601
[No Abstract] [Full Text] [Related]
8. Single pretransplant donor-specific transfusion in cadaver and living related donor renal transplantation.
Alexander JW; Davies CB; First MR; Cofer BR; Munda R; Madden RL; Hariharan S; Schroeder TJ
Transplant Proc; 1993 Feb; 25(1 Pt 1):485-7. PubMed ID: 8438389
[No Abstract] [Full Text] [Related]
9. Role of suppressor cells in cyclosporine-treated allograft recipients.
Kerman RH; Flechner SM; Van Buren CT; Lorber MI; Kahan BD
Transplant Proc; 1987 Feb; 19(1 Pt 2):1580-3. PubMed ID: 2950632
[No Abstract] [Full Text] [Related]
10. In vitro donor-specific hyporesponsiveness and T cell subsets in renal allograft recipients.
Bas J; Mestre M; Griñó JM; Massip E; Castelao AM; Romeu A; González L; Valls A; Buendía E
Allergol Immunopathol (Madr); 1993; 21(4):136-40. PubMed ID: 8237717
[TBL] [Abstract][Full Text] [Related]
11. Three year experience of donor specific transfusion and concomitant cyclosporine A.
Hillis AN; Duguid J; Evans CM; Bone JM; Sells RA
Transplant Proc; 1987 Feb; 19(1 Pt 3):2248-9. PubMed ID: 2978890
[No Abstract] [Full Text] [Related]
12. Early or delayed use of cyclosporine in HLA-mismatched living-related donor renal transplants.
Sumrani N; Hong JH; Daskalakis P; Cacciarelli TV; Markell MS; Sommer BG
Transplant Proc; 1993 Jun; 25(3):2246-7. PubMed ID: 8516888
[No Abstract] [Full Text] [Related]
13. Optimization of donor specific blood transfusion in kidney transplantation.
Cheigh JS; Suthanthiran M; Stubenbord WT; Fotino M; Riggio RR; Schechter N; Stenzel KH; Rubin AL
Transplant Proc; 1987 Feb; 19(1 Pt 3):2250-1. PubMed ID: 2978891
[TBL] [Abstract][Full Text] [Related]
14. Comparative study of two protocols for living-related renal transplantation: donor-specific transfusion versus cyclosporine.
Mazzali M; Alves Filho G; Alves MA; de Faria JB
Transplant Proc; 1995 Apr; 27(2):1832-3. PubMed ID: 7725525
[No Abstract] [Full Text] [Related]
15. Immunosuppressive factors in patients after donor-specific transfusion with administration of cyclosporine.
Yuzawa K; Otsuka M; Yu Y; Sharma N; Iwasaki H; Fukao K; Iwasaki Y
Transplant Proc; 1991 Feb; 23(1 Pt 2):1036-8. PubMed ID: 1824884
[No Abstract] [Full Text] [Related]
16. Changes in donor-specific cell-mediated lympholysis (CML) response associated with success of early steroid withdrawal in DST-azathioprine-treated renal transplant recipients.
Burlingham WJ; Grailer A; Sollinger HW
Transplant Proc; 1989 Feb; 21(1 Pt 2):1818-9. PubMed ID: 2523595
[No Abstract] [Full Text] [Related]
17. Management of induction phase of immunosuppression in liver graft recipients: prevention of oversuppression by immune monitoring.
Settmacher U; Döcke WD; Manger T; Fietze E; Rückert R; Wolff H; Volk HD
Transplant Proc; 1993 Aug; 25(4):2703-4. PubMed ID: 8356723
[No Abstract] [Full Text] [Related]
18. Acquired donor-specific hyporesponsiveness in long-term kidney allograft recipients.
Reinsmoen NL; Matas A; Kaufman D; Sutherland D; Najarian JS; Bach FH
Transplant Proc; 1991 Feb; 23(1 Pt 1):141-2. PubMed ID: 1824968
[No Abstract] [Full Text] [Related]
19. HLA-DR matching is effective in reducing posttransplant costs in renal allograft recipients on triple therapy.
Taylor CJ; Bayne AM; Welsh KI; Morris PJ
Transplant Proc; 1993 Feb; 25(1 Pt 1):210-1. PubMed ID: 8438273
[No Abstract] [Full Text] [Related]
20. Kinetics of antidonor mixed lymphocyte culture responses in donor specific transfusions plus azathioprine-treated patients.
Burlingham WJ; Grailer A; Sparks-Mackety EM; Sondel PM; Sollinger HW
Transplant Proc; 1987 Feb; 19(1 Pt 3):2255-7. PubMed ID: 2978892
[No Abstract] [Full Text] [Related]
[Next] [New Search]
